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Abstract
Background. Renal transplant recipients (RTR)
mainly die of premature cardiovascular disease.
Traditional cardiovascular disease risk factors are
prevalent in RTR. Additionally, non-traditional risk
factors seem to contribute to the high risk. The impact
of renal dysfunction was compared with traditional
risk factors for cardiovascular morbidity and mortality
in 1052 placebo-treated patients of the ALERT trial.
Methods. All patients were on cyclosporine-based
immunosuppressive therapy, follow-up was 5–6 years
and captured endpoints included cardiac death,
non-cardiovascular death, all-cause mortality, major
adverse cardiac event (MACE), non-fatal myocardial
infarction (MI) and stroke.
Results. A calculated 84 mmol/l increase in serum
creatinine was needed to double the risk for cardiac
death, an increase of 104mmol/l to double the risk for
non-cardiovascular death and an increase of 92 mmol/l
to double the risk for all-cause mortality. MACE
risk was doubled if serum creatinine was elevated by
141 mmol/l, age was increased by 23 years, or LDL-
cholesterol by 2mmol/l. Diabetes increased the
incidences of cardiac death, all-cause mortality,
MACE, stroke and non-fatal MI. A serum creatinine
increase of 130 mmol/l, or 20 years increase in age
was calculated as similar in risk for cardiac death,
all-cause mortality and MACE, and comparable to
risk of diabetes in RTR.
Conclusion. An increase in serum creatinine of
80–100mmol/l doubles the risk for cardiac death,
non-cardiovascular death and all-cause mortality in
RTR. An increase of 130 mmol/l in serum creatinine or
20 years increase in age is comparable to risk of
diabetes.
Keywords: cardiovascular disease; creatinine;
mortality; renal transplantation; risk factors;
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Introduction
Renal transplant recipients (RTR) mainly die of
premature cardiovascular disease (CVD) [1].
Traditional CVD risk factors are highly prevalent in
RTR and immunosuppression may induce or aggravate
hypertension, diabetes and hyperlipidaemia [2,3]. Prior
to transplantation, these patients have mostly been
exposed to uraemia-speciﬁc non-traditional risk factors
such as increased oxidative stress, chronic inﬂamma-
tion, hyperhomocysteinaemia, malnutrition, calcium–
phosphate imbalance and volume overload [4]. The
intermediate endpoint for CVD, left ventricular hyper-
trophy (LVH), has been described in 50–70% of RTR
and has been used as part of a prognostic index for
mortality in these patients [4,5].
Ducloux et al. [6] showed that Framingham risk
model underestimated CVD risk in the RTR and hyper-
tension was not associated with coronary heart disease
risk. We recently demonstrated that in RTR every
100 mmol/l (1.13mg/dl) increase in baseline serum
creatinine increased the risk for cardiac death, non-
cardiovascular death, all-cause mortality and major
adverse cardiac event (MACE). The inﬂuence of serum
creatinine on the risk increment remained signiﬁcant
after adjustment for other risk factors [7]. To study the
importance of renal transplant dysfunction in CVD
and mortality risk further, we have set renal transplant
dysfunction into the perspective of traditional risk
factors. Calculating risk factor increases needed
to achieve certain risks enabled us to compare the
impact of renal transplant dysfunction with traditional
risk factors.
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Methods
The Assessment of Lescol in Renal Transplantation
(ALERT) trial was an investigator-initiated and
investigator-led, randomized, double-blind, parallel group
study designed to investigate the effects of ﬂuvastatin on
cardiac and renal endpoints in RTR. The ALERT study
design, baseline data and outcomes have been previously
published [8,9].
Participants
Adult RTR were recruited from nephrology and transplant
clinics in Belgium, Denmark, Finland, Norway, Sweden,
Switzerland, the UK and Canada. The patients had received
renal or combined renal and pancreas transplants >6 months
prior to randomization. All patients were on cyclosporine-
based immunosuppression, but no one received statins prior
to inclusion. Total fasting cholesterol ranged from 4–9mmol/l
(4–7mmol/l for those with previous cardiac event). Patients,
who had had an acute rejection episode in the last 3 months,
or who had a predicted life expectancy of <1 year were
excluded. The recorded endpoints included cardiac death,
non-cardiovascular mortality, all-cause mortality, non-fatal
myocardial infarction (MI), stroke and MACE (deﬁned as
cardiac death, non-fatal MI or coronary revascularization
procedure). Single event per patient was accounted for. The
critical events committee (CEC) consisted of two nephrolo-
gists and two cardiologists who were unaware of treatment
assignment. All endpoints were adjudicated by the CEC
and classiﬁed after agreement by consensus majority vote [9].
The present analysis was performed in 1052 patients in the
placebo arm of the study only, because this was considered
to be the ‘cleanest’ approach, preferable to including and
adjusting for the treatment arm. The study adhered to the
International Conference on Harmonisation Guidelines and
for good clinical practice and was done in accordance with the
Declaration of Helsinki. All participants provided written
informed consent, and the Ethics Committee at each
participating centre approved the trial.
Statistical analysis
The statistical analysis plan of the main study has been
described previously [9]. Univariate and multivariate Cox
proportional hazards models were used to analyse the
impact of serum creatinine, low density lipoprotein
(LDL)-cholesterol, age and the presence of diabetes on
predeﬁned endpoints. Risk ratio (RR) was calculated
per 100 mmol/l (1.13mg/dl) increment in serum creatinine,
per 1mmol/l increment in LDL-cholesterol, and per 1 year
increment in age. Diabetes was accounted for as a binary
variable. A large number of potential risk factors were
analysed for each outcome before stepwise selection of
variables, using P-values of 0.1 for inclusion, was applied in
the multivariate model. The potential risk factors were age,
diabetes, previous transplant rejection, smoking, previous
coronary heart disease, cerebrovascular disease, peripheral
vascular disease, LVH, number of transplants, LDL-
cholesterol, high density lipoprotein (HDL)-cholesterol,
polycystic kidney disease, serum creatinine, systolic blood
pressure, pulse pressure, HLA-DR mismatch, body mass
index, proteinuria, time on dialysis prior to transplantation
and time since transplantation. Themultivariatemodels referred
to include only variables selected by the stepwise procedure.
Between-group differences were assessed with 2. Logistic
regression models were used to calculate the probabilities of
experiencing events at continuous risk factor levels. The
increments needed to achieve certain risks were calculated
using the estimated relative risk from the univariate model
and obtaining the increment needed as the value of the
independent variable resulting in a doubling of the relative
risk or in relative risk corresponding to diabetes mellitus. All
analyses were performed using the SAS statistics package
(SAS Institute, Cary, NC). P<0.05 was regarded signiﬁcant.
Results
Between June 1996 and October 1997, 2102 patients
were recruited to the ALERT trial, of whom, 1052 were
randomly assigned to the placebo arm and followed for
5–6 years. During that time there was a ‘drop-in’ rate
of 14% for statin use in this arm of the study, compared
with 7% in the active treatment (ﬂuvastatin 40–80mg)
arm, mainly occurring late in the study. The patients in
the placebo arm of the study experienced 54 cardiac
deaths. In addition, there were 66 patients with deﬁnite
MI and 65 patients died of non-cardiovascular causes.
The baseline demographic and clinical characteristics
for the placebo group are presented in Table 1.
Risk factor analyses
Risk-factor analyses of baseline serum creatinine, age,
diabetes, and LDL-cholesterol concentrations were
performed. Diabetes mellitus was a signiﬁcant risk
factor for cardiac death, all-cause mortality, MACE,
non-fatal MI and stroke, both in univariate and
multivariate models. Diabetes did not increase the RR
for non-cardiovascular death (Figure 1). Every 1 year
increase in age resulted in RR increments for cardiac
death, non-cardiovascular death, all-cause mortality,
MACE, non-fatal MI, and stroke. Multivariate
analyses conﬁrmed the independence of age as risk
factor for these endpoints (Table 2). Every 1mmol/l
increase in baseline LDL-cholesterol was associated
with increments in MACE and non-fatal MI risks in
univariate and multivariate models (Table 2). Using
logistic regression models, the probabilities of reaching
endpoints at different risk factor levels could be
estimated (Figure 2).
Doubling of risk
We calculated the estimated increments needed in
serum creatinine, age and LDL-cholesterol to double
the RR for predeﬁned endpoints This provided an
interesting comparison of risk factors, e.g. the risk of
cardiac death was doubled if serum creatinine increased
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by 84 mmol/l (1.0mg/dl), or age increased by 14 years.
Non-cardiovascular death risk doubled with 104 mmol/l
increase in serum creatinine, or with every 10 years
increase in age. All-cause mortality risk doubled with
either 92 mmol/l increment in baseline serum creatinine,
or with increase by 12 years in age. An estimated age
increment of 23 years, LDL-cholesterol increment of
2mmol/l or 141 mmol/l increment in serum creatinine
were associated with doubling the risk for MACE.
To double the RR for non-fatal MI in RTR, 23 years
increment in age or 2.0mmol/l increment in LDL-
cholesterol was needed. The risk of stroke was doubled
with 14 years increment in age (Table 3).
Diabetes as risk factor
Comparing diabetic and non-diabetic RTR, it was
found that non-diabetic patients had a cardiac death
rate of 4% and diabetic patients 10.1% (P¼ 0.0004)
during the 5-year follow-up. The all-cause mortality
rate was 10.4% for non-diabetic patients and 24.6% for
diabetic patients (P<0.0001). Non-fatal MI rate was
5.3% for non-diabetic and 11.1% for diabetic RTR
(P¼ 0.0026); the stroke rate was 2.5% for non-diabetic
patients, while it was 12.1% for diabetic patients
(P<0.0001). The corresponding ﬁgures for MACE
were 11.3% and 19.1%, respectively (P¼ 0.0028)
(Figure 1).
Diabetes vs other risk factors
The estimated increments needed in risk factors that
are continuous variables to correspond to the risk
associated with diabetes mellitus for different endpoints
were also calculated. It was revealed that in order
to correspond to risk for cardiac death in diabetic
Table 1. Baseline demographic and clinical characteristics of the placebo group (n (%) or mean±SD)
Demographic and clinical characteristics Placebo (n¼ 1052)
Age, years 50.0±11.0
Male 686 (65.2%)
Diastolic blood pressure, mmHg 85.6±10.0
Systolic blood pressure, mmHg 144.0±19.1
Body mass index, kg/m2 25.8±4.6
LDL-cholesterol, mmol/l (mg/dl) 4.1±1.0 (159±39)
HDL-cholesterol, mmol/l (mg/dl) 1.4±0.4 (54±15)
Triglycerides, mmol/l (mg/dl) 2.2±1.5 (196±134)
Serum creatinine, mmol/l (mg/dl) 142±51(1.58±0.58)
Diabetes mellitus* 199 (19%)
Time taking for renal replacement therapy, months 89±58
Time on dialysis prior to transplantation, months 28±42
First transplantation 900 (85.6%)
Type of last transplant: cadaveric donor 822 (78.1%)
Hypertension 777 (73.9%)
Current smoker 185 (17.6%)
History of angina pectoris 77 (7.3%)
Previous myocardial infarction 34 (3.2%)
History of cerebrovascular disease 60 (5.7%)
History of peripheral vascular disease 78 (7.4%)
Known family history of coronary heart disease 124 (11.8%)
Concomitant immunosuppressive therapy** 680 (64.6%)
Azathioprine 848 (80.6%)
Prednisolone 10 (1.0%)
Cyclophosphamide 159 (15.1%)
Mycophenolate mofetil 224 (21.3%)
Other
Concomitant cardiovascular medication** 999 (95%)
Any cardiovascular drug 353 (33.6%)
Acetylsalicylic acid 26 (2.5%)
Dipyridamole 94 (8.9%)
Coumarin or warfarin 627 (59.6%)
b-Blockers 738 (70.2%)
Calcium antagonists 529 (50.3%)
ACE inhibitors or AIIRA 573 (54.5%)
Diuretics 170 (16.2%)
a-Blockers 373 (35.5%)
Other
From reference [7], with permission from Blackwell Publishing.
ACE, angiotensin-converting enzyme, AIIRA, angiotensin-II-receptor blocker.
*Includes pre-existing diabetes mellitus and post-transplantation diabetes mellitus.
**Taken at least once during study.
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RTR (RR¼ 2.82), an estimated 125 mmol/l increase in
serum creatinine or 21 years increase in age would be
needed. The all-cause mortality risk in diabetes mellitus
(RR¼ 2.61) corresponded to a baseline serum creati-
nine increase of 128mmol/l or an age increase of 16 years
in a non-diabetic RTR. To equal the RR of diabetic
patients for non-fatal MI (RR¼ 2.41), an estimated
increase in age of 30 years or increase in LDL-cholesterol
by 2.6mmol/l was needed. A diabetic RTR had a
stroke risk (RR¼ 5.43) which corresponded to that
of a 35 year older non-diabetic RTR. The MACE
risk of the diabetic RTR (RR¼ 1.93) was achieved if
a non-diabetic RTR had a baseline serum creatinine
increase of 135 mmol/l, was 22 years older or had
a LDL-cholesterol increase of 1.9mmol/l (Table 4).
Discussion
In the ALERT trial, ﬂuvastatin treatment reduced the
risk for cardiac death and non-fatal MI, but had no
effect on renal endpoints in RTR [9,10]. Analyses in the
placebo arm of the trial revealed that renal dysfunction
was an independent risk factor for cardiac death, non-
cardiovascular death, all-cause mortality, MACE and
graft loss [7,11,12]. Increased age was associated with
mortality and cardiovascular morbidity risk, LDL-
cholesterol was a risk factor for MACE and non-fatal
MI, and diabetes was associated with increased risk
of cardiac death, all-cause mortality, MACE, non-fatal
MI and stroke [13].
Doubling of risk
Calculating the estimated increments needed in
baseline serum creatinine, age and LDL-cholesterol
to double the risk for the captured endpoints, set the
relative inﬂuence of these risk factors into a new
perspective, and to our knowledge, no similar compar-
isons of risk factors has been made previously.
Surprisingly, only a moderate degree of renal transplant
dysfunction doubled CVD and mortality risk, similar
to the impact of increased age or LDL-cholesterol.
Therefore, the prominence of renal dysfunction as a
risk factor in comparison with age and LDL-cholesterol
is not to be underrated in RTR.
Diabetes
Diabetes mellitus as pre-existing disease or post-
transplant complication has a negative impact on patient
and renal graft survival [14,15]. In the present study,
diabetes mellitus was associated with an increased risk
for non-fatal MI, stroke, MACE, cardiac death and
all-cause mortality, but not for non-cardiovascular
mortality. We also calculated the estimated increments
needed in creatinine, age and LDL-cholesterol to
equal the risk by diabetes mellitus. Only a moderate
degree of renal dysfunction led to a risk of cardiac
death, MACE and all-cause mortality which was
comparable to diabetes mellitus. However, because
CVD risk factors occur simultaneously, the
assessed total risk should be based on their co-existence
as well.
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Fig. 1. Endpoint incidences in non-diabetic (n¼ 853) and diabetic (n¼ 199) renal transplant recipients. *P<0.003; **P<0.0005
***P<0.0001.
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Renal dysfunction
Even minute renal dysfunction in other populations has
been associated with increased mortality and cardio-
vascular risk [16]. The CVD risk has been shown to
increase progressively with deteriorating glomerular
ﬁltration rate and is increased signiﬁcantly by the time
serum creatinine is elevated [16]. The study does not
reveal the mechanisms by which renal dysfunction
contributes to the increased risk. In RTR, non-
traditional risk factors such as inﬂammation, oxidative
stress, hyperhomocysteinaemia, endothelial dysfunc-
tion and arterial stiffness may have greater than
estimated inﬂuence on CVD and mortality. Ducloux
et al. [6] have demonstrated that high C-reactive protein
and homocysteine are associated with increased cor-
onary heart disease risk in RTR. In RTR, serum
creatinine has a strong association with graft failure,
which is associated with increased cardiac death and
all-cause mortality [11,17]. In our study population,
graft loss increased the incidences of non-fatal MI,
MACE, non-cardiovascular death and all-cause
mortality [7].
Cardiac mortality patterns in renal patients differs
from the general population with the predominance of
sudden cardiac death explained by the high prevalence
of uraemic cardiomyopathy, and the resultant pre-
disposition to spontaneous arrhythmia [18,19]. In the
present study, LDL-cholesterol was associated with
increased risk for MACE and non-fatal MI, but not
for cardiac death. On the other hand, serum creatinine
was associated with cardiac death and MACE risk,
but not with the risk of non-fatal MI alone [7,13].
To further establish renal dysfunction as a risk
factor for mortality and cardiovascular complications,
interventional studies are needed. Immunosuppressive
therapy constitutes a prevailing toxic burden on the
kidney transplant, and in patients who undergo other
organ transplantation impairment of native healthy
kidney function has been observed during calcineurin-
inhibitor-based immunosuppression [20]. Although
corticosteroids are not considered nephrotoxic,
they adversely affect CVD risk factors such as hyper-
tension, hyperlipidaemia and diabetes. In the ALERT
trial, hypertension and diabetes were also associated
with the risk for renal endpoints [11]. Therefore,
cardiovascular outcomes in patients on different
immunosuppressive regimens should be compared.
It could be assumed that the use of a less nephro-
toxic immunosuppressive regimen led to reduced
mortality.
In conclusion, renal transplant dysfunction is a
strong and independent risk factor for CVD and
mortality, and comparable with traditional risk factors
such as diabetes mellitus, age and LDL-cholesterol. An
estimated increase in serum creatinine by 80–100 mmol/l
doubles the risk for cardiac death, non-cardiovascular
death and all-cause mortality in RTR. An increase
by 130 mmol/l in serum creatinine or 20 years increase
in age results in cardiac death, all-cause mortality and
MACE risk comparable with diabetes in RTR.
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Fig. 2. (A) Endpoint probabilities at baseline creatinine levels. From reference [7] with permission from Blackwell Publishing.
( ) All-cause mortality (P<0.0001) ( ) Cardiac death (P<0.0001) ( ) Non-cardiovascular death (P¼ 0.0005) ( ) MACE
(P¼ 0.0007) ( ) Non-fatal MI (NS) ( ) Stroke (NS). (B) Endpoint probabilities at baseline age. ( ) All-cause mortality
(P<0.0001) ( ) Cardiac death (P<0.0001) ( ) Non-cardiovascular death (P¼ 0.0001) ( ) MACE (P¼ 0.0001) ( ) Non-fatal
MI (P¼ 0.0351) ( ) Stroke (P¼ 0.0002). (C) Endpoint probabilities at baseline LDL-cholesterol levels. ( ) All-cause mortality (NS)
( ) Cardiac death (NS) ( ) Non-cardiovascular death (NS) ( ) MACE (P<0.0001) ( ) Non-fatal MI (P¼ 0.0038)
( ) Stroke (NS). All P-values have been calculated by univariate Cox regression analysis.
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